 |
MRK
Merck and Co Inc $MRK Somewhat Down. Emerging Combination Agent from Merck Will Garner Peak Year: http://bit.ly/a4Yoja
MRK
Merck and Co Inc $MRK Slightly Dropping. Chartpoppers.com releases Investment Analysis on Bristol Mye: http://bit.ly/b2HG1F
MRK
Merck and Co Inc $MRK Slightly Dropping. Chartpoppers.com releases Investment Analysis on Bristol Mye: http://bit.ly/afl28Q
MRK
Merck and Co Inc $MRK Slightly Dropping. Sanofi Nears Decision On Combining Animal Unit With Merck: http://bit.ly/awvYwd
MRK
Merck and Co Inc $MRK Slightly Dropping. Sanofi Nears Decision On Combining Animal Unit With Merck: http://bit.ly/b32Fbu
MRK
Merck and Co Inc $MRK Slightly Dropping. Sanofi Nears Decision On Combining Animal Unit With Merck: http://bit.ly/b5wrdt
MRK
Merck and Co Inc $MRK Shot down To Over 4%. Wall Street Plummets On Jobs Data, Bank of America (NYSE: BA: http://bit.ly/cNj7Oc
MRK
Merck and Co Inc $MRK Shot down To Over 4%. Merck Partners with BC Centre for Excellence in HIV/AIDS for: http://bit.ly/bbbCHx
MRK
RT @Loftus: Maybe this'll work, re $MRK's ProQuad vaccine delay: http://tinyurl.com/yaufzgf It works!
MRK
RT @Loftus: Merck's $MRK ProQuad vaccine delay: http://tinyurl.com/yaufzgf
MRK
Maybe this'll work, re $MRK's ProQuad vaccine delay: http://tinyurl.com/yaufzgf
MRK
Merck and Co Inc $MRK Down Past 2%. Merc Announces Election of New Director: http://bit.ly/9NbVMB
MRK
Merck and Co Inc $MRK Down Past 2%. Most Stocks Lower on Tepid Economic Data. Dow Laggards: PFE,: http://bit.ly/9XVrLX
MRK
Toyota: I smell a Vioxx. The fallacy of vividness will take hold, push the stock lower and create an opportunity. Still too early $tm $mrk
MRK
$MRK $PFE..drug stocks with nice dividend
MRK
$MRK could tag 3950 at this rate
MRK
Just saw $MRK - ran a full pt today
MRK
$MRK Medical journal Lancet fully retracts 1998 study linking MMR vaccine to autism, citing "incorrect" elements of research
MRK
Merck and Co Inc $MRK Not Moving. inVNT Reports Financial Results for Year-End 2009: http://bit.ly/9NjQis
MRK
Merck and Co Inc $MRK Not Moving. SDI Reports: Merck Sales Reps Ranked No. 2 by Cardiologists: http://bit.ly/9VTm4p
MRK
Merck and Co Inc $MRK Somewhat Up. U.S. District Court Rules Against Merck & Co., Inc. In T: http://bit.ly/cpuJib
MRK
Merck and Co Inc $MRK Somewhat Up. U.S. District Court Rules Against Merck & Co., Inc. In TEMOD: http://bit.ly/beaLg5
MRK
Analysts Hate These Five #Stocks, So Buy Them Now: John Dorfman
http://bit.ly/am9e17 $lly $mrk $pfe #cna $low $$
MRK
Scientists Make Monumental Advance In the Fight Against Aids ($GILD,$MRK) http://bit.ly/decYd7
MRK
Merck and Co Inc $MRK Fairly Up. How to Make Billions of Dollars Without Really Trying: http://bit.ly/dBsX1L
MRK
Merck and Co Inc $MRK Fairly Up. How to Make Billions of Dollars Without Really Trying: http://bit.ly/bGB7St
MRK
POS? That's a good thing at $MRK! ;-) -- >RT @Dereklowe: Xconomy has a look inside the Merck-Sirna acquisition http://bit.ly/aco5u5
MRK
RT @carmenhill8 - Merck and Co Inc $MRK Not Moving. Bristol-Myers 4Q profit rises on sales boost, gain: http://brokerz.com/_58E/
MRK
RT @carmenhill8 - Merck and Co Inc $MRK Not Moving. Bristol-Myers 4Q profit rises on sales boost, gain: http://brokerz.com/_58E/
Merck & Co. Inc. - MRK Insiders
No Insiders
We have no insiders for Merck right now.
Know someone who is an insider on Merck & Co. Inc.?
Let us know.
Merck & Co. Inc. - MRK information
Merck & Co., Inc. provides products for human and animal health in the United States and internationally. The company?s Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents. Its products comprise Singulair, a leukotriene receptor antagonist for the treatment of asthma and allergic rhinitis; Cozaar, Hyzaar, Vasotec, and Vaseretic, the hypertension and/or heart failure products; Fosamax and Fosamax Plus D for treating osteoporosis; Januvia and Janumet for type 2 diabetes; Cosopt and Trusopt, the ophthalmological products; Zocor, an atherosclerosis product; Maxalt for acute migraine; Propecia to treat male pattern hair loss; Arcoxia to treat arthritis and pain; Proscar to treat symptomatic benign prostate enlargement; and Emend for the prevention of chemotherapy-induced and post-operative nausea and vomiting. Merck & Co.?s Vaccines segment comprises human health vaccines, such as preventative pediatric, adolescent, and adult vaccines. Its products include Gardasil to prevent cervical cancer, pre-cancerous and low-grade lesions, vulvar and vaginal pre-cancers, and genital warts; Varivax to prevent chickenpox; ProQuad, a pediatric combination vaccine against measles, mumps, rubella, and varicella; M-M-R II, a vaccine against measles, mumps, and rubella; RotaTeq to protect against rotavirus gastroenteritis in children; Zostavax for preventing shingles; Primaxin and Cancidas, anti-bacterial/anti-fungal products; Isentress, Crixivan, and Stocrin, antiretroviral therapies for the treatment of HIV infection; and Invanz for the treatment of infection. Merck & Co. has research, collaboration, or licensing agreements with Neuromed Pharmaceuticals, Ltd.; ARIAD Pharmaceuticals, Inc.; GTX, Inc.; Idera Pharmaceuticals; Japan Tobacco Inc.; Galapagos NV; AstraZeneca plc; Metabasis Therapeutics Inc.; and Addex Pharmaceuticals Ltd. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey....
www.merck.com
Founded in 1851
MERCK & CO. INC. (MRK:NYSE)
LAST $36.88 USD
CHANGE TODAY +0.21 0.57%
VOLUME 15.3M
As of 6:40 PM 03/11/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of MERCK & CO. INC. (MRK)
|
OPEN
$36.35
|
PREVIOUS CLOSE
$36.67
|
|
|
DAY HIGH
$36.95
|
DAY LOW
$36.10
|
|
|
52 WEEK HIGH
01/21/10 - $41.56
|
52 WEEK LOW
03/12/09 - $21.66
|
|
|
MARKET CAP
114.9B
|
AVERAGE VOLUME 10 D
13.5M
|
|
|
EPS TTM
$3.25
|
SHARES OUTSTANDING
3.1B
|
|
|
EX-DATE
03/11/10
|
P/E TTM
11.3x
|
|
|
DIVIDEND
$1.52
|
DIVIDEND YIELD
4.12%
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Merck: Study of Vytorin effectiveness to continue
AP Digital - 03/11/2010 5:46 PM ET
Final Glance: Pharmaceuticals companies
AP Digital - 03/11/2010 5:45 PM ET
*Midday Glance: Pharmaceuticals companies
AP Digital - 03/11/2010 1:04 PM ET
*Amylin shares fall ahead of diabetes drug decision
AP Digital - 03/11/2010 12:46 PM ET
*Early Glance: Pharmaceuticals companies
AP Digital - 03/11/2010 10:49 AM ET
Key developments for MERCK & CO. INC. (MRK)
Intervet, Merial To Divest Assets
03/10/2010
Intervet, Inc. and Merial Limited may have to divest of some assets so that competition authorities can approve tie up of Merck & Co. Inc. and Sanofi-Aventis. Both units may be forced to divest of vaccines for poultry business as the companies have a strong presence in that market segment. Chris Viehbacher, CEO of Sanofi-Aventis, admitted the possibility for asset divestitures but at the same time noted they would not be numerous.
Merial And Intervet May Have To Divest Assets
03/10/2010
The Competition watchdog may ask Merial Limited and Intervet International B.V., to divest off some assets in order to get the green light for their tie-up. Both the companies may be forced to divest of their poultry vaccines business as the companies have a strong presence in that market segment. Chris Viehbacher, CEO of Sanofi-Aventis, admitted the possibility for asset divestitures but at the same time noted, they would not be numerous. Merial Limited is controlled by Sanofi-Aventis and Merck & Co. Inc. controls Intervet International.
Merck & Co. Inc. and Sanofi-Aventis Form Joint-Venture
03/9/2010
Merck & Co. Inc. and Sanofi-Aventis announced that they are merging their animal health businesses into a joint-venture making and marketing everything from tick fighters to vaccines and with annual sales of $5.3 billion. The combined company will have a global market share of 29%, well ahead of Pfizer's Fort Dodge unit with 20%. It will have operations across North America, Latin America, Europe and most emerging markets.
MRK Competitors
| Company | Last | Change |
| Abbott Laboratories | $55.54 USD | +0.51 |
| Amgen Inc | $57.49 USD | -0.29 |
| Bristol-Myers Squibb Co | $25.96 USD | +0.31 |
| Eli Lilly & Co | $35.82 USD | +0.48 |
| Takeda Pharmaceutical Co Ltd | ¥4,075 JPY | +50.00 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | MRK | Industry Range |
| Price/Earnings | 6.5x |
|
| Price/Sales | 3.7x |
|
| Price/Book | 1.9x |
|
| Price/Cash Flow | 8.9x |
|
| TEV/Sales | 3.1x |
|
|
MRK |
||
|
MRK transactions
| Type Date |
Target |
|
Buyback
November 24, 2009 |
-- |
Merck & Co. Inc. - MRK news
Sanofi-aventis and Merck to Create a Global Leader in Animal Health
2010-03-09 03:32:18
Quote: NYSEMRKNewsNYSESNYNewsNYSEMRKNews) announced today that sanofi-aventis has exercised its option tocombine Merial with Intervet/Schering-Plough, Merck’s Animal Healthbusiness, to create a global leader in Animal Health.The new joint venture will be equally-owned by Merck and sanofi-aventis.The formation of this new animal health joint venture is subject toexecution of final agreements, antitrust review in the United States,Europe and other countries and other customary closing conditions. ...Read article
Merck, Sanofi combining animal medicine businesses
2010-03-09 03:32:17
Quote: (AP) -- Two of the world's biggest pharmaceutical companies said Tuesday they are uniting their animal health businesses in a deal to become the top dog in the veterinary industry.Merck & Co. and France's Sanofi-Aventis SA said they'll jointly own the combined business, which will have a share of about 29 percent in the $19 billion-a-year global market for medicines for pets and livestock. That's well ahead of the current leader, Pfizer Inc.'s Fort Dodge unit, which has about 20 percent of the m...Read article
[$$] Sanofi, Merck to Revive Animal-Health Joint Venture
2010-03-09 03:32:16
Quote: BY PETER LOFTUSAND MIMOSA SPENCERSanofi-Aventis SA and Merck & Co. plan to combine their animal-health businesses in a joint venture that would renew old ties and, according to the companies, create the largest seller of animal drugs and vaccines in the world. Paris-based Sanofi said Tuesday it exercised an option to combine its Merial animal-health unit with the Intervet/Schering-Plough business owned by U.S.-based Merck. Sanofi obtained the option last year when it gained full control of Mer...Read article
Sanofi-Aventis, Merck form animal-health venture
2010-03-09 03:32:16
Keywords: , SNY, Sanofi Aventis, SAN, Sanofi-Aventis, MRK, Merck & Co Inc New
Quote: TEL AVIV (MarketWatch) -- Sanofi-Aventis and Merck & Co. agreed to form a 50-50 animal-health joint venture, the companies said Tuesday. Under the terms, the Paris health-care giant/quotes/comstock/13*!sny/quotes/nls/sny(SNY38.15,+0.01,+0.03%)/quotes/comstock/24s!e:san(FR:SAN56.27,+0.52,+0.93%) will exercise an option to combine Merial with Intervet/Schering-Plough, the animal-health business of the Whitehouse Station, N.J., health-care giant./quotes/comstock/13*!mrk/quotes/nls/mrk(MRK37.35,...Read article
Merck, Sanofi Create Animal Health Giant
2010-03-09 03:32:15
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, Joseph Woelfel ,Drugs
Quote: (TheStreet) -- Merck(MRK) and France's Sanofi-Aventis (SNY) plan to combine their animal health businesses.The combination of Sanofi's Merial unit and Merck's Intervet/Schering Plough will be equally-owned by both companies, which said Tuesday the completion of the transaction is expected to occur in roughly the next 12 months.Merial makes the Frontline flea product for cats and dogs and its operations are predominantly located in the Americas. Intervet/Schering-Plough focuses mainly on vaccines...Read article
Bristol-Myers: 60 drugs in testing to boost sales
2010-03-05 03:44:57
Quote: Onglyza, which competes with Merck & Co.'s popular, well-established Januvia, brought in only $4 million in the fourth quarter, far below analysts' forecasts of $30 million to $91 million."While it may be a little slower than" initially anticipated, said Cornelius, "the product is a great product and has every hope of reaching" sales expectations.Chief Operating Officer Lamberto Andreotti said Bristol-Myers has been able, despite increased competition, to increase sales of key existing products,...Read article
Stopping The Killer
2010-03-05 03:44:57
Keywords: India, Cervical Cancer, HPV, Human Papilloma Virus, Women, Health, Vaccine, Catalan Institute Of Oncology, Spain, Chittaranjan National Cancer Institute
Quote: Only Gardasil, from Merck & Co.(MRK -news-people), protects against strains 6 and 11. Cervarix, from GSK, only protects against the 16 and 18 strains of HPV. Put together, these vaccines only protect men from 2 to 4 of the more than 100 strains of the HPV virus. With at least 39,600 men affected by anal cancer in India each year, and with an LGBT population of at least 30 million, you cannot deny the need for the vaccine among men. But then again, the vaccine is not fail-proof.
This article ...Read article
Australian court: Vioxx doubled heart attack risk
2010-03-05 03:44:56
Quote: pharmaceutical firm Merck & Co. over its since-recalled drug Vioxx. The painkiller was taken off the global market in 2004 after research showed it raised the risk of heart attacks and strokes.Melbourne, sued Merck and its Australian subsidiary, Merck Sharpe & Dohme, arguing the painkiller caused him to have a heart attack in 2003, leaving him unable to work.The judge found that Merck Sharpe & Dohme failed in its duty of care by not warning Peterson's doctor about the drug's potential cardiovasc...Read article
[$$] Australian Judge Holds Merck Liable
2010-03-05 03:44:56
Quote: BY BILL LINDSAY SYDNEY—An Australian court Friday held Merck & Co. liable in the heart attack of a patient using the painkiller Vioxx, but it rejected allegations that the U.S. drug maker was negligent in keeping the drug on the market before withdrawing it six years ago. Melbourne Federal Court Judge Christopher Jessup ruled that Graeme Peterson should be entitled to compensation after Merck's local distribution arm failed to adequately warn his doctor of potential cardiovascular risks f...Read article
Merck Statement on Vioxx® Judgment in Australia
2010-03-05 03:44:56
Quote: The Court dismissed all claims againstMerck & Co., Inc. specifically finding that Merck was not negligent inits development, scientific study and sale of Vioxx. Merck and MSDAustralia disagree with the limited portions of the Court’s findingsthat were against MSD Australia and intend to appeal them.September 2004.About Merckwww.merck.comForward-Looking StatementThis news release includes “forward-looking statements†within themeaning of the safe harbor provisions of the United...Read article
UPDATE - Merck unit held liable in Australian Vioxx case
2010-03-05 03:44:55
Keywords: Pharmaceuticals (sub-industry),United States of America,Australia,Asia,Judicial processes/court cases/court decisions,Legislation,Crime law and justice,General News,Politics International Affairs and Law,Company News item,Economic news, EC, business/finan
Quote: UPDATE 1-Merck unit held liable in Australian Vioxx case * Melbourne court awards A$288,000 against MSD Australia * Court says Vioxx was unfit for sale due to heart risk(Adds detail on award, plaintiff law firm, background) LONDON, March 5 (Reuters) - Merck & Co's (MRK.N) one-time
blockbuster arthritis drug Vioxx doubled the risk of heart
attacks and was not fit for sale, an Australian court said on
Friday, in a ruling against the U.S. group's Australian unit. Federal Court judge Christopher...Read article
Pfizer pneumonia shot helps HIV-infected patients
2010-03-04 06:07:02
Keywords: Pharmaceuticals (sub-industry),United States of America,United Kingdom,Western Europe,Europe,Malawi,Africa,Emerging countries,Economic news, EC, business/financial pages,
Quote: GlaxoSmithKline has a rival vaccine called Synflorix that
acts against 10 strains, and Merck sells Pneumovax 23, which
fights 23 strains and is the only vaccine of its type approved
in the United States for adults. Scientists tested the Prevnar 7 vaccine on almost 500
predominantly HIV-infected adults in Blantyre, Malawi. Alongside their main finding, they also found the vaccine
prevented disease even in HIV-infected people whose immune
systems were very weak and who were starting to develop AID...Read article
US STOCKS-Wall St flat as White House pushes regulation
2010-03-04 06:07:02
Keywords: United States of America,Equities,Labour; Employment; Unemployment,Banks (industry group),Financials,Mergers and Acquisitions (including Changes of Ownership),Pharmaceuticals - diversified,Pharmaceuticals (sub-industry),Fund management and asset allocatio
Quote: Big pharmaceutical companies Merck & Co (MRK.N) and Pfizer
Inc (PFE.N) were among the biggest drags on the Dow
Industrials. Merck fell 0.6 percent to $37.15, while Pfizer dropped 1.9
percent to $17.26. Pfizer also was affected by news its
Alzheimer's drug, Dimebon, did not meet the main goals of a
late-stage clinical trial Adding to the market's jitters, U.S. banks would be banned
from proprietary trading and other large financial firms would
face limits on such activity, according to draft ...Read article
Q&A with Kley: Merck chairman mum on layoffs, site closures
2010-03-03 07:45:08
Quote: Karl-Ludwig Kley, the chairman of the executive board at German drug maker Merck KGaA, was in Boston Tuesday roughly a day after his company announced it was acquiring Billerica, Mass.-based Millipore Corp. (MYSE: MIL) for $7.2 billion. So far, both sides say the deal’s goal is to grow the local laboratory instrument maker, not consolidate it into Merck’s massive footprint. That said, Kley did not rule out layoffs at the Billerica location. He spoke about the planned transaction and ...Read article
Merck Unveils Positive Asthma Drug Test
2010-03-03 07:45:06
Keywords: Merck & Co. asthma treatment, Asmanex Twisthaler Foradil Aerolizer, Food and Drug Administration
Quote: Merck & Co. (MRK) shares were up slightly Tuesday afterthe company reported positive results from a late-stage test of its asthma treatment.The treatment combines two well-known asthma drugs, Asmanex Twisthaler and Foradil Aerolizer. In a study of patients 12and older, the combination was more effective at preventing severe asthma attacks than either drug on its own.The results of the trial were presented Tuesday at the American Academy of Allergy, Asthma & Immunology's annual meeting.Th...Read article
Merck Reports Results of Phase III Study of Investigational Oral Allergy Immunotherapy Tablet (AIT) in Patients Ages 5-17 with Grass Pollen Allergy
2010-03-03 07:45:06
Quote: NEW ORLEANS--(BUSINESS WIRE)--In new data from a Phase III study in 345 children and adolescents (ages5-17 years), patients with grass pollen allergic rhinoconjunctivitistreated with Merck's investigational sublingual grass (Phleum Pratense)allergy immunotherapy tablet (AIT) showed a 26 percent greaterimprovement in the total combined score (daily symptom score and dailymedication score), compared to patients receiving placebo (p=0.001).Allergic rhinoconjunctivitis, or runny nose and itchy, wate...Read article
UK cost agency recommends Roche arthritis drug
2010-03-03 07:45:04
Keywords: Pharmaceuticals (sub-industry),Switzerland,Western Europe,Europe,United States of America,Chemicals,Biotechnology,Regulation and enforcement,United Kingdom,Central and Eastern Europe,Healthcare,Business activities,Company News item,Economic news, EC, busi
Quote: Abbott Laboratories' (ABT.N) Humira; Pfizer's (PFE.N) and
Amgen's (AMGN.O) Enbrel; and Merck & Co (MRK.N) and Johnson &
Johnson's (JNJ.N) Remicade were only recommended for use after
the failure of another anti-TNF drug only in the context of
research. Bristol-Myers Squibb's (BMY.NBen HirschlerDavid Holmes)......Read article
Merck cites positive study results on allergy drug
2010-03-03 07:45:04
Quote: NEW YORK (AP) -- Merck & Co. said Tuesday new data from a late-stage study showed its allergy treatment candidate met key effectiveness goals when compared with placebo.The company said patients treated with its sublingual grass, or Phleum Pratense, allergy immunotherapy tablet showed a 26 percent greater improvement in allergy symptoms than patients on placebo. The late-stage study, which involved 345 patients aged between 5 and 17 years, focused on allergic rhinoconjunctivitis, or runny no...Read article
AIG, SanDisk, Shanda Games, HSBC are big movers
2010-03-02 06:38:07
Quote: taxpayers.Millipore Corp., up $10.49 at $104.90An analyst raised his price target after Germany's Merck KGaA said it will pay $6 billion in cash to buy the biotech equipment maker.Dillard's Inc., up $3.16 at $20.03Though sales dropped 10 percent, the department store operator was able to significantly lower costs and inventory to post a profit.MSCI Inc., down $1.39 at $28.59MSCI agreed to buy RiskMetrics Group Inc. for about $1.55 billion in a cash and stock deal.HSBC Holdings PLC, down $3.34 at...Read article
[$$] Stocks in the Spotlight Monday
2010-03-02 06:38:07
Quote: Millipore (MIL) Shares of the biotech-supply company rose 11% Monday after agreeing to be acquired by Merck (MRK) for $107 a share, or about $7.2 billion in total, including debt. The two companies said the merger would achieve significant scale in the high-margin, high-growth specialty biologics. Jefferies & Co. analyst Jon Wood raised his price target match the offer. "Given what we perceive was a thorough review process, the all-cash nature of the transaction structure, and Merck's commitment...Read article